Starna extends range of CRMs to cover Far UV to NIR spectral region - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Starna extends range of CRMs to cover Far UV to NIR spectral region

Starna Scientific’s Reference Material and Calibration manufacturing laboratory has extended the Starna range of Certified Reference Materials (CRMs), providing the most comprehensive range of UV/Visible/NIR Materials currently available under the scope of ISO Guide 34 + ISO/IEC 17025 accreditation for Reference Material producers.

"We now hold a unique position in the production of CRMs for wavelength and Transmittance scales, certified in accordance with ISO Guide 34 and ISO/IEC 17025, for the complete Far UV to NIR spectral region (190 – 2850 nm)," explained Keith Hulme, Starna's Managing Director.

The Starna® Lifetime Guarantee is offered on all Starna® manufactured Certified Reference Materials (CRMs). The guarantee provides for a free of charge replacement should the assigned values move outside the expanded uncertainty budget within the recertification period of two years, subject to conditions of use/care and recertification by Starna at least every two years.

The CRMs are essential for ISO/IEC accredited laboratories, pharmaceutical QA/QC or metrology departments enabling the provision of Operational Qualification (OQ) and Performance Qualification (PQ) of UV/Visible/NIR instrumentation using 'Industry Standard' protocols.

Starna is the only Reference Material producer accredited to both ISO Guide 34 and ISO/IEC 17025 in the UV/Visible/NIR spectral range. The CRMs the company now provide extend the scope of available materials for spectral range, band width and photometric linearity.

Visit www.starna.com, email sales@starna.com or call + 44 (0) 20 8501 5550 for more information.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
FindPharma Custom Search

Click here